| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Alto Neuroscience, Inc. | Director | Stock Option (right to buy) | 1,590 | $5,040 | $3.17 | 08 Mar 2024 | Direct |
| Entrada Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 38,000 | 01 Jun 2025 | Direct | ||
| Candel Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 28,480 | 04 Jun 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| CADL | Candel Therapeutics, Inc. | 04 Jun 2025 | 1 | $0 | 4 | Director | 06 Jun 2025, 16:36 |
| CADL | Candel Therapeutics, Inc. | 04 Jun 2025 | 0 | $0 | 3 | Director | 06 Jun 2025, 16:31 |
| TRDA | Entrada Therapeutics, Inc. | 01 Jun 2025 | 1 | $0 | 4 | Director | 03 Jun 2025, 08:13 |
| TRDA | Entrada Therapeutics, Inc. | 01 Jun 2025 | 0 | $0 | 3 | Director | 03 Jun 2025, 08:11 |
| ANRO | Alto Neuroscience, Inc. | 08 Mar 2024 | 2 | +$16,239 | 4 | Director | 12 Mar 2024, 16:49 |
| ANRO | Alto Neuroscience, Inc. | 08 Mar 2024 | 0 | $0 | 3 | Director | 12 Mar 2024, 16:47 |